Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of 131I-huA33 with Concurrent Capecitabine-Reference-Cited by-同舟云学术

Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of 131I-huA33 with Concurrent Capecitabine

Published:2014-02-20 Issue:4 Volume:55 Page:534-539
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Herbertson Rebecca A.,Tebbutt Niall C.,Lee Fook-Thean,Gill Sanjeev,Chappell Bridget,Cavicchiolo Tina,Saunder Tim,O’Keefe Graeme J.,Poon Aurora,Lee Sze Ting,Murphy Roger,Hopkins Wendie,Scott Fiona E.,Scott Andrew M.

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Reference40 articles.

1. Cancer statistics, 2012

2. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

3. Wu C, Goldberg RM. Colorectal cancer in 2012: revisiting landmark trials and identifying new therapies. Nat Rev Clin Oncol. 2013;10:71–72.

4. Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

5. Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances and impending challenges for the radiopharmaceutical sciences in oncology;The Lancet Oncology;2024-06

2. Proteomics reveals unique identities of human TGF-β-induced and thymus-derived CD4+ regulatory T cells;Scientific Reports;2022-11-24

3. One-step synthesis of a radioiodinated anti-microRNA-21 oligonucleotide for theranostics in prostate tumor xenografts;Colloids and Surfaces A: Physicochemical and Engineering Aspects;2022-09

4. Radiotheranostics in oncology: current challenges and emerging opportunities;Nature Reviews Clinical Oncology;2022-06-20

5. A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers;Investigational New Drugs;2022-04-11